There are also suggestions that these agents can specifically cause apoptosis of BCL6 dependent B-cell lines and primary human B-cell lymphomas and this site on the BTB-POZ domain is, therefore, a validated target for drug discovery. The gene discussed is BCL6; the disease is B-cell non-Hodgkin lymphoma.